EXELIXIS INC. for EXELIXIS INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Proposals related to drug pricing, including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, to include CMMIs GUARD and GLOBE models, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. Development and implementation of national security policies impacting biotechnology, including regulatory frameworks that may affect cross-border investments, research collaborations, and business operations
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES M. FENTON | — |
| ERIN HERMANCE | — |
| JARED DANIEL MICHAUD | — |
Taxation/Internal Revenue Code TAX
Federal tax policy issues affecting the biopharmaceutical industry, including provisions related to business taxation, research and development incentives, and broader fiscal legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES M. FENTON | — |
| ERIN HERMANCE | — |
| JARED DANIEL MICHAUD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.